Short answer · Medically reviewed summary · Last updated: 2023-07-13
Asherson’s Syndrome, also known as Catastrophic Antiphospholipid Syndrome (CAPS), is a rare and severe autoimmune disorder characterized by the formation of blood clots in small blood vessels throughout the body. This condition primarily affects young to middle-aged adults, with a slight predominance in males. Due to its rarity, the prevalence of Asherson’s Syndrome/CAPS is not well-established.
What is the prevalence of Asherson’s Syndrome / Catastrophic Antiphospholipid Syndrome?
Prevalence of Asherson’s Syndrome / Catastrophic Antiphospholipid Syndrome: how many people are affected worldwide, differences by sex and region, with sources.
Asherson’s Syndrome, also known as Catastrophic Antiphospholipid Syndrome (CAPS), is a rare and severe autoimmune disorder characterized by the formation of blood clots in small blood vessels throughout the body. This condition primarily affects young to middle-aged adults, with a slight predominance in males.
Due to its rarity, the prevalence of Asherson’s Syndrome/CAPS is not well-established. However, it is estimated to occur in approximately 0.5-1% of individuals with antiphospholipid syndrome (APS), a more common autoimmune disorder characterized by the presence of antiphospholipid antibodies.
Asherson’s Syndrome/CAPS is a life-threatening condition that can lead to multiple organ failure if not promptly diagnosed and treated. The exact cause of this syndrome is still unknown, but it is believed to involve a combination of genetic and environmental factors.
Early recognition and aggressive treatment are crucial in managing Asherson’s Syndrome/CAPS. Treatment typically involves high-dose anticoagulation therapy, immunosuppressive drugs, and supportive care to prevent further clot formation and organ damage.
